Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Tanios Bekaii‐Saab

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7721-1699; OpenAlex author ID A5074891676, A5132667651, A5135674831, A5153113748; NIH RePORTER profile ID 8661877. Sources: ClinicalTrials.gov.

Their work

Papers
84 (first author 4, last author 19)
Trials
2 (principal investigator on 2)
Grants
1
Labs led
4
Collaborators
325
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: 1 paper · 2012: 1 paper · 2013: 5 papers · 2014: 5 papers · 2015: 8 papers · 2016: 8 papers · 2017: 4 papers · 2018: 7 papers · 2019: 4 papers · 2020: 5 papers · 2021: 9 papers · 2022: 1 paper · 2023: 9 papers · 2024: 4 papers, 1 grant · 2025: 3 papers, 1 trial · 2026: 10 papers

Papers 50 of 84

  1. Adjuvant Chemotherapy Is Not Associated With Improved Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma With Persistent Lymphovascular Invasio… Co-author DOI 10.1002/jso.70414↗
  2. NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI … Co-author DOI 10.1016/j.esmoop.2025.106043↗
  3. Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgr… Co-author DOI 10.1016/j.esmoop.2026.108307↗
  4. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. Last author DOI 10.1038/s41591-026-04327-4↗
  5. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  6. Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer. Co-author DOI 10.1038/s41598-026-40757-3↗
  7. Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligence. Co-author DOI 10.1038/s41698-026-01543-6↗
  8. Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer. Last author DOI 10.1080/14712598.2026.2738708↗
  9. KRAS in pancreatic cancer: from molecular biology to transformative therapeutics. Co-author DOI 10.1186/s13045-026-01863-x↗
  10. Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm. Last author DOI 10.2147/dddt.s559325↗
  11. Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic… Co-author DOI 10.1016/j.esmoop.2025.105534↗
  12. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Co-author DOI 10.1080/14796694.2025.2458458↗
  13. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study. Co-author DOI 10.1093/oncolo/oyaf271↗
  14. Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review. Last author DOI 10.1016/j.ejca.2023.113471↗
  15. Corrigendum to "Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review" [Eur J Cancer 198 (2024) 113471]. Last author DOI 10.1016/j.ejca.2024.113941↗
  16. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-1444↗
  17. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16101861↗
  18. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adapti… Co-author DOI 10.1016/j.eclinm.2023.101897↗
  19. Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). Last author DOI 10.1016/j.ejca.2023.02.030↗
  20. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-lab… Co-author DOI 10.1016/s0140-6736(23)01366-1↗
  21. Real-world data validation of the PurIST pancreatic ductal adenocarcinoma gene expression classifier and its prognostic implications Co-author DOI 10.1101/2023.02.23.23286356↗
  22. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline r… Co-author DOI 10.1136/jitc-2023-007586↗
  23. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  24. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Cl… Co-author DOI 10.1200/po.22.00706↗
  25. Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot St… Co-author DOI 10.1245/s10434-022-12328-z↗
  26. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. Co-author DOI 10.5306/wjco.v14.i8.285↗
  27. Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma. Last author DOI 10.1016/j.pan.2022.06.009↗
  28. Optimizing Chemotherapy Choice in the Treatment of Advanced Pancreatic Cancer-It Is Complicated. First author DOI 10.1001/jamanetworkopen.2021.34458↗
  29. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Last author DOI 10.1002/onco.13717↗
  30. Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer. First author DOI 10.1002/psp4.12725↗
  31. The role of microbiome in pancreatic cancer. Co-author DOI 10.1007/s10555-021-09982-2↗
  32. Contemporary Management of Pancreatic Cancer from an Internist Perspective. Co-author DOI 10.1016/j.amjmed.2020.11.009↗
  33. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. First author DOI 10.1016/j.ejca.2021.03.028↗
  34. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A … Co-author DOI 10.1016/j.pan.2020.10.029↗
  35. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Last author DOI 10.14309/ctg.0000000000000414↗
  36. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Last author DOI 10.3389/fonc.2021.794009↗
  37. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.011↗
  38. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Co-author DOI 10.1016/j.pan.2020.06.015↗
  39. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000708↗
  40. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. Co-author DOI 10.1097/mpa.0000000000001479↗
  41. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2020-0086↗
  42. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.11.002↗
  43. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  44. Sister Mary Joseph Nodule in Advanced Pancreatic Adenocarcinoma Identified on 18F-FDG PET/MRI. Co-author DOI 10.2967/jnmt.119.225961↗
  45. Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers11081068↗
  46. Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. Co-author DOI 10.1080/21541248.2016.1251383↗
  47. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-311585↗
  48. Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. Last author DOI 10.3390/cancers10060193↗
  49. Highlights in pancreatic cancer from the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium: commentary. Co-author PMID 29742086↗
  50. Therapeutic advances in metastatic pancreatic adenocarcinoma and related cancers: focus on evidence-based and sequenced approaches to survival extension in met… Co-author PMID 30807558↗

Trials 2

  1. BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma Principal investigator NCT07226856↗
  2. 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery Principal investigator NCT00288093↗

Grants 1

  1. Gastrointestinal Cancer Program P30CA015083↗

Closest collaborators

The 25 strongest of 325 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitesh J. Borad · 11 shared papers, 2017–2026 · strength 1.92
  2. Mohamad Bassam Sonbol · 9 shared papers, 2017–2026 · strength 1.53
  3. Teresa Mercade Macarulla · 9 shared papers, 2019–2026 · strength 1.48
  4. Zev A. Wainberg · 8 shared papers, 2021–2026 · strength 1.43
  5. Daniel H. Ahn · 14 shared papers, 2015–2024 · strength 1.31
  6. Shubham Pant · 8 shared papers, 2014–2026 · strength 1.27
  7. Hani M. Babiker · 6 shared papers, 2021–2026 · strength 1.25
  8. Eileen Mary O'Reilly · 6 shared papers, 2023–2026 · strength 1.19
  9. Eric Van Cutsem · 6 shared papers, 2023–2026 · strength 1.14
  10. Sreenivasa Rao Chandana · 5 shared papers, 2023–2025 · strength 1.10
  11. Andrew Scott Paulson · 5 shared papers, 2023–2026 · strength 0.99
  12. Roberto Pazo-Cid · 5 shared papers, 2023–2026 · strength 0.99
  13. Davide Melisi · 5 shared papers, 2023–2026 · strength 0.99
  14. Richard A Hubner · 5 shared papers, 2023–2026 · strength 0.99
  15. Robert R. McWilliams · 7 shared papers, 2020–2024 · strength 0.94
  16. Vincent M. Chung · 5 shared papers, 2015–2026 · strength 0.86
  17. Cody R. Eslinger · 2 shared papers, 2026 · strength 0.79
  18. Amit Mahipal · 5 shared papers, 2020–2024 · strength 0.72
  19. Wen Wee Ma · 5 shared papers, 2020–2024 · strength 0.69
  20. Pedro Luiz Serrano Usón · 4 shared papers, 2021–2026 · strength 0.62
  21. Gregory B. Lesinski · 13 shared papers, 2013–2019 · strength 0.61
  22. Chee‐Chee Stucky · 3 shared papers, 2023–2026 · strength 0.61
  23. Andrew Peter Dean · 4 shared papers, 2021–2025 · strength 0.58
  24. Laura M. Woods · 2 shared papers, 2024 · strength 0.56
  25. Ben George · 2 shared papers, 2026 · strength 0.55

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.